mTOR regulates EMT in prostate cancer through the RhoA and Rac1 pathways.[58] Transcriptomic analysis and omics validation showed that mTOR expression was reduced by both SHP099 and embelin, explaining the reversal of EMT at the molecular level. This evidence concerns the gene RHOA and prostate carcinoma.